FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 104 filers reported holding FATE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $195 | -92.4% | 91,864 | -82.9% | 0.01% | -91.9% |
Q2 2023 | $2,555 | +17.8% | 536,831 | +41.1% | 0.11% | +8.8% |
Q1 2023 | $2,169 | -99.7% | 380,537 | +1681.9% | 0.10% | +88.9% |
Q1 2022 | $828,000 | +55.3% | 21,356 | +134.4% | 0.05% | -19.4% |
Q4 2021 | $533,000 | +13.6% | 9,111 | +15.0% | 0.07% | +8.1% |
Q3 2021 | $469,000 | +172.7% | 7,921 | -54.9% | 0.06% | +87.9% |
Q1 2018 | $172,000 | -38.6% | 17,580 | -75.1% | 0.03% | -48.4% |
Q3 2017 | $280,000 | -15.4% | 70,677 | -30.8% | 0.06% | -31.2% |
Q2 2017 | $331,000 | – | 102,169 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |